Pfizer Inc.
PD-L1 antagonist combination treatments
Last updated:
Abstract:
The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
Status:
Grant
Type:
Utility
Filling date:
15 Jun 2016
Issue date:
22 Dec 2020